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Abstract
Background: Osteosarcoma is a bone tumor that often affects children and young adults. Although a combination
of surgery and chemotherapy has improved the survival rate in the past decades, local recurrence and metastases
still develop in 40% of patients. A definite therapy is yet to be determined for osteosarcoma. Anti- tumor
compound and a metabolite of estrogen, 2-methoxyestradiol (2-ME) induces cell death in osteosarcoma cells. In
this report, we have investigated whether interferon (IFN) pathway is involved in 2-ME-induced anti-tumor effects
in osteosarcoma cells.
Methods: 2-ME effects on IFN mRNA levels were determined by Real time PCR analysis. Transient transfections
followed by reporter assays were used for investigating 2-ME effects on IFN-pathway. Western blot analyses were
used to measure protein and phosphorylation levels of IFN-regulated eukaryotic initiation factor-2 alpha (eIF-2a).
Results: 2-ME regulates IFN and IFN-mediated effects in osteosarcoma cells. 2 -ME induces IFN gene activity and
expression in osteosarcoma cells. 2-ME treatment induced IFN-stimulated response element (ISRE) sequence-dependent
transcription and gamma-activated sequence (GAS)-dependent transcription in several osteosarcoma cells. Whereas, 2-
ME did not affect IFN gene and IFN pathways in normal primary human osteoblasts (HOB). 2-ME treatment increased
the phosphorylation of eIF-2a in osteosarcoma cells. Furthermore, analysis of osteosarcoma tissues shows that the
levels of phosphorylated form of eIF-2a are decreased in tumor compared to normal controls.
Conclusions: 2-ME treatment triggers the induction and activity of IFN and IFN pathway genes in 2-ME-sensitive
osteosarcoma tumor cells but not in 2-ME-resistant normal osteoblasts. In addition, IFN-signaling is inhibited in
osteosarcoma patients. Thus, IFN pathways play a role in osteosarcoma and in 2-ME-mediated anti-proliferative
effects, and therefore targeted induction of IFN signaling could lead to effective treatment strategies in the control
of osteosarcoma.
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Background
Osteosarcoma is the most common malignant primary
bone tumor in children and adolescents. It is the 6th
leading cancer in children under 15. Osteosarcoma
accounts for 2.4% of all malignancies in pediatric
patients and approximately 20% of all bone cancers
[1,2]. Current standard treatment is to use neoadjuvant
chemotherapy followed by surgical resection. Although a
combination of surgery and chemotherapy has led to
improved survival rate, a definite therapy is yet to be
determined for this disease. 2-Methoxyestradiol (2-ME),
which acts as a potential anti-tumor agent in several
types of cancer, has been shown to block cell growth
and induce apoptosis in osteosarcoma cells [3-8].
IFNs are a family of cytokines synthesized and secreted
by most cell types that elicit pleiotropic biological effects
[9]. Three main classes of IFNs namely, a, b and g have
been identified and classified as type I (a, b) and type II
(g). IFNs which induce anti-viral, anti-angiogenic, anti-pro-
liferative, anti-cancer effects and immune modulatory
effects, have been shown to block the progression of
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cancer in vitro and in vivo [9-11]. The biological effects of
IFNs are mediated through IFN-regulated genes. Three
major IFN-regulated pathways involving RNA-dependent
protein kinase (PKR)/the eukaryotic initiation factor (eIF)-
2a system, 2-5A synthetase/RNase L system and Janus
Kinase (JAK)/signal transducer and activator of transcrip-
tion (STAT) system have been identified [9]. PKR/eIF2a
system mainly mediates type I IFN effects and the protein
synthesis factor eIF-2a functions as the effector of PKR-
induced effects in this pathway [9]. IFN’s role in mainte-
nance therapy has been investigated in osteosarcoma and
other cancers. Several studies have demonstrated that
IFNs block osteosarcoma growth in patients, animal mod-
els, and in cultured cells [10,12]. IFNa has been studied as
a maintenance therapy after post-operative chemotherapy
with cisplatin, doxorubicin and methotrexate [12,13]. In
murine model of osteosarcoma, IFNa reduces the tumor
growth and the metastatic nodules in the lungs [14]. IFNb
has been shown to block the growth of osteosarcoma cells
in vitro. In addition IFN enhances antitumor activity of
chemotherapeutic agents [15,16]. We have demonstrated
that the anti-growth effects of 2-ME are accompanied by
increases in IFN mRNA levels in osteosarcoma cells [5]. In
this report, we have investigated the regulation and asso-
ciation of IFN pathways in 2-ME-mediated effects in
osteosarcoma cells.
Methods
Primary human osteoblast (HOB) cells
HOB cells were established from cancellous bone
obtained as surgical waste material from orthopedic sur-
gical procedures in accordance with a Mayo Clinic Insti-
tutional review board (IRB) approved protocol and
cultured as explants to generate the osteoblast-like
monolayers, as described [17].
Cell culture
Human osteosarcoma cells (MG63, 143B, KHOS and
HOS) and HOB cells were grown in DMEM/F12 med-
ium containing 10% charcoal-stripped fetal bovine
serum (FBS), penicillin, streptomycin and geneticin (300
μg/mL) and maintained at 37 C under 5% CO2.
2-ME was purchased from Sigma Chemical Co. (St.
Louis, MO). Stock solutions of the metabolites at their
respective concentrations were made in 95% ethanol.
Human IFN a, b and g were obtained from Mayo Clinic
Pharmacy and suspended in DMEM/F12 medium with-
out serum.
Reporter assays
The reporter constructs containing g-activated sequence
(GAS) elements, kindly provided by Dr. Aseem Kumar
(Laurentian University, Sudbury, Ontario, Canada),
interferon-stimulated response element (ISRE) obtained
from Stratagene (La Jolla, CA) and IFN-b gene promoter
sequences, kindly provided by Dr. Barbara Sherry (North
Carolina State University, Raleigh, NC) were used.
Osteosarcoma cells plated in 6-well plates (1.5 × 106
cells/well) were transfected with the indicated reporter
luciferase constructs at 60% cell confluence using the
transfection reagent Lipofectamine, as described in the
manufacturer’s protocol (Invitrogen, Carlsbad, CA).
IFN-lucifease construct was transfected using the trans-
fection reagent FuGene, as described in the manufac-
turer’s protocol (Promega, Madison, WI). All
transfections performed had a control plasmid contain-
ing Renilla Luciferase (Promega, Madison, WI) which
allowed normalization of luciferase units. Twenty-four
hours post transfection, the cells were treated with 2-
ME (10 μM) and IFN (2000 units/mL). The cells were
harvested after 48 h of treatment or as indicated and
suspended in 300 μL of passive lysis buffer provided in
a luciferase assay kit (Promega) and read on a TD-20E
luminometer (Turner, Sunnyvale, CA).
RNA isolation and analysis by RT PCR
Cells were plated at 106 cells per flask in T-75 culture
flasks one day prior to metabolite treatment. The next
day, cells were replaced with fresh medium containing
10 μM concentrations of 2-ME and incubated for differ-
ent periods of time. The cells were harvested and the
cell pellets were used for RNA isolation. Total cellular
RNA was extracted and isolated using a modified
organic solvent method, and the RNA yields were deter-
mined spectrophotometrically at 260 nm. The levels of
IFNa, IFNb and control actin mRNA were analyzed by
Real-time quantitative PCR using ABI 7900HT System
(Perkin-Elmer Applied Biosystems, Foster City, CA) as
described. The primers used were: IFNa forward:
5’GCTC ACCC ATTT CAAC CAGT3’; IFNa reverse:5’
GATG GTTT CAGC CTTT TGGA3’; IFNb forward:5’
GTGT CAGA AGCT CCTG TGGC3’; IFNb reverse:
5’CTTC AGTT TCGG AGGT AACC3’; Actin forward:
5’ TGCCTCAGGGCA3’ and Actin reverse:
5’GCTGTGCTATCCCTGTAC3’.
Normal and osteosarcoma tissues
Osteosarcoma tissues and normal muscle tissues were
obtained through a protocol submitted and approved by
the institutional review board (IRB), an internal review
committee at Mayo Clinic represented by several clinical
faculty members including pathologists, oncologists,
orthopedic surgeons, legal and administrative team
members. The tumor tissues were obtained through sur-
gical resection. The normal muscle tissues collected in
this study were normal muscle tissues adjacent to osteo-
sarcoma tissues occurring within the same patient. The
histology was reviewed by fellowship-trained
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musculoskeletal pathologists to confirm proper diagno-
sis. After collection, the tissues were stored at -70°C
until processed for protein analysis.
Protein analysis and western blot hybridization
Protein analysis was carried out as described [4]. Briefly,
vehicle- and 2-ME-treated cells were harvested and
lysed by suspending in cell lysis buffer. After centrifuga-
tion at 10,000 × g for 10 min, the supernatant was col-
lected, and the protein concentration was determined by
Bradford protein assay. Normal and tumor tissues
obtained from patients according to the IRB-approved
protocol were homogenized in lysis buffer and the pro-
tein concentration was determined. Cytoplasmic extract
containing protein (60 μg) was analyzed by Western
blot hybridization using anti-phosphoeIF-2a (1: 1000
dilution), anti- eIF-2a (1: 3000 dilution) and anti-glycer-
oldehyde 3-phosphate dehydrogenease (GAPDH) (1:
5000 dilution) antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA). The expression levels of proteins on
the western blots were quantitated using densitometer
and PD Quest 7.4.0 software (BioRad, Hercules, CA).
Statistical analysis
All values are expressed as means ± standard error. The
data is representative of three independent experiments.
Significant differences between groups were determined
by Fisher’s protected least significant difference post hoc
test for multiple-group comparisons following detection
of significance by one-way analysis of variance
(ANOVA). P < 0.005 was considered statistically
significant.
Results
2-ME effect on IFN gene in osteosarcoma cells
We have demonstrated previously that 2-ME treatment
induces IFN mRNA levels in MG63 osteosarcoma cells.
In order to determine whether 2-ME treatment affects
IFN mRNA levels in osteosarcoma cell types with differ-
ent metastatic potentials, we have carried out Real time
PCR and measured on IFN mRNA levels in MG63 and
143B osteosarcoma cells. 2-ME treatment induced IFNa
and b mRNA levels in MG63 osteosarcoma cells (Figure
1A and 1B). IFNa mRNA levels were increased by 2.7-,
2-, 3- and 4.5-fold, and IFNb mRNA levels were
increased by 3-, 2-, 4- and 7.8-fold at 4, 8, 16 and 24 h,
respectively. 2-ME increased IFNa mRNA levels at 16 h
by 8-fold compared to vehicle control but did not have
any effect at other time points (8 and 24 h) analyzed
(Figure 1C). 2-ME treatment induced IFNa and b
mRNA levels in 143B osteosarcoma cells (Figure 1C
and 1D). 2-ME increased IFNa mRNA levels at 16 h by
8- fold compared to vehicle control but did not have
any effect at other time points (8 and 24 h) analyzed
(Figure 1C). 2-ME treatment increased IFNb mRNA
levels at 8 and 24 h by 2- and 3.5-fold and did not
affect at 16 h compared to the vehicle controls (Figure
1D). Our results show that 2-ME does not regulate
IFNa and b mRNA levels in normal osteoblasts (Figure
1E and 1-F).
In order to determine whether 2-ME has a direct
effect on IFN genes, we have investigated the effect of
2-ME on IFNb gene-driven luciferase activity by transi-
ent transfection assays in human osteosarcoma cells.
Relative to vehicle control, 2-ME treatment stimulated
the luciferase activity by 9- and 4.5-fold in MG63
and143B osteosarcoma cells, respectively (Figure 2). Our
results show that 2-ME does not regulate IFNb gene-
driven luciferase activity in normal HOB cells (Figure 2).
2-ME effects on IFN-dependent effects in osteosarcoma
cells
To determine whether 2-ME treatment induces IFN-
dependent transcription, we have tested the effect of 2-
ME treatment on interferon-stimulated response ele-
ment (ISRE) and g-activated sequence (GAS). 2-ME
actions on luciferase reporter constructs driven by ISRE
and GAS sequences were determined by transient trans-
fection assays in human osteosarcoma cells. 2-ME treat-
ment induced IFN-stimulated response element (ISRE)
sequence-dependent transcription by 4-, 8-, 9- and 4.5-
fold in MG63, 143B, KHOS and HOS cells, respectively
(Figure 3). 2-ME stimulated gamma-activated (GAS)
sequence-dependent transcriptions by 4-, 5- and 10-fold
in MG63, 143B and KHOS cells, respectively (Figure 4).
2-ME, however, showed no effect on GAS-dependent
transcription in HOS osteosarcoma cells. Our studies
from normal osteoblasts shown in Figure 5 indicate that
both ISRE and GAS-dependent luciferase activities are
not altered in primary HOB cells after transient expres-
sion of ISRE-and GAS-luciferase plasmid constructs fol-
lowed by treatment of 2-ME indicating that 2-ME
treatment does not affect ISRE- and GAS-dependent
transcriptions in normal osteoblasts.
2-ME effect on IFN-regulated eukaryotic initiation factor
(eIF)-2a
To determine the effect of 2-ME on eIF-2a, the effector
of IFN-regulated anti -proliferative and anti-tumor sig-
nals we have investigated the protein extracts from vehi-
cle and 2-ME-treated osteosarcoma cells. Our results
indicate that the eIF-2a phosphorylation increases in
the presence of 2-ME treatment. 2-ME treatment
increases eIF-2a phosphorylation after 16 h by 15-, 4, 2-
and 2-fold in MG63, 143B, KHOS and HOS cells com-
pared to vehicle (Figure 6A &6B) [18]. 2-ME treatment
does not affect eIF-2a and phosphor eIF-2a in HOB
cells (Figure 6A). Our results show that the levels of
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non-phosphorylated eIF-2a and the control glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) are not
affected in the presence of vehicle control and 2-ME-
treatment (Figure 6A).
Regulation of eIF-2a protein in osteosarcoma patients
Several experimental studies and clinical trials show that
osteosarcoma responds to IFN therapy. To investigate
whether IFN pathway is regulated in osteosarcoma, we
Figure 1 2-ME effects on IFN mRNA levels. A)MG63 IFNa mRNA; B) MG63 IFNb mRNA; C)143B IFNa mRNA; D)143B IFNb mRNA; E) HOB IFNa
mRNA; F) HOB IFNb mRNA. Cells were treated with Veh and 2-ME (10 μM) for 24 hrs. Total RNA was isolated from cells and analyzed by real
time PCR. Values are the mean ± SE(n = 6 replicate cultures) * P < 0.05 vs Veh.
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Figure 2 2-ME effect on IFN gene promoter Activity in Osteosarcoma Cells. MG63 and 143B cells transiently transfected with
pblueIFNluciferase were treated with Veh and 2-ME (10 μM) for 24 hrs and the luciferase reported activity was analyzed. Values are the mean+
SE(n = 6 replicate cultures).
Figure 3 2-ME effect on ISRE-Luciferase Activities in Osteosarcoma Cells. MG63 and 143B cells transiently transfected with ISRE-luciferase
were treated with Veh and 2-ME (10 μM) for 24 hrs and the luciferase reporter activity was analyzed. Values are the mean+ SE(n = 6 replicate
cultures) * P < 0.05 vs Veh.
Wimbauer et al. BMC Cancer 2012, 12:93
http://www.biomedcentral.com/1471-2407/12/93
Page 5 of 10
Figure 4 2-ME effect on GAS-Luciferase Activities in Osteosarcoma Cells. Cells transiently transfected with GAS-luciferase were treated with
Veh and 2-ME (10 μM) for 24 hrs and the luciferase reporter activity was analyzed. Values are the mean+ SE(n = 6 replicate cultures) * P < 0.05
vs Veh.
Figure 5 2-ME effect on GAS- and ISRE-activities in normal osteoblasts. HOB cells transiently transfected with GAS- and ISRE-luciferase were
treated with Veh and 2-ME(10 μM) for 24 hrs and the luciferase reporter activity was analyzed. Values are the mean+ SE(n = 6 replicate cultures).
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have analyzed the regulation of eIF-2a protein. Figure 6
shows the levels of phosphorylated and total levels of
eIF-2a from four representative normal control muscle
and osteosarcoma tissues from 15 patients. The repre-
sentative blot from four tissues is shown in Figure 6C.
Quantitation of signals from protein analysis by western
blot hybridization shows that ratio of peIF-2a to eIF-
2a decreases from 3- to 42-fold in 11 of 15 osteosar-
coma tissues analyzed, demonstrating an increased
phosphorylation of eIF-2a in normal compared to
tumor (Figure 6D). The phosphorylation of eIF-2a is
increased by 3-fold and 9-fold in 2 tumor tissues com-
pared to normal and does not alter in 2 patients ana-
lyzed. Whereas, the levels of non-phosphorylated eIF-2a
and the control glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) are not affected in control and tumor tis-
sues (Figure 6C).
Discussion
Unlike the parent compound, 17b-estradiol, the metabo-
lite 2-ME shows anti-growth effects and functions as a
potential therapeutic agent in several types of cancer.
We have previously shown that 2-ME induces cell death
in osteosarcoma cells but not in normal osteoblasts
[4,5]. In this report, we demonstrate that 2-ME regulates
IFN pathway in a number of osteosarcoma cell lines.
2-ME induces IFN gene promoter activity, expression,
and IFN-dependent transcriptional activities in low
tumorigenic MG63 and high tumorigenic 143B osteosar-
coma cells. 2-ME-dependent effects on IFN genes and
pathways are specific to osteosarcoma cells and are
associated with anti-proliferative effects. Whereas 2-ME
does not influence IFN and IFN-dependent pathways in
normal HOB cells which have been previously shown to
be resistant to the anti-growth activities of 2-ME [5].
Our results also show that the eIF-2a protein and the
downstream effectors of IFN pathway are regulated by
2-ME treatment in several osteosarcoma cell lines. In
addition, eIF-2a phosphorylation is decreased in osteo-
sarcoma tumor patients compared to normal. Our
results suggest that IFN pathway is involved in osteosar-
coma growth and regulation.
It has been reported earlier that 2-ME-mediated cell
death is accompanied by increases in IFNb mRNA levels
in low metastatic MG63 osteosarcoma cells [5]. Current
investigation shows that 2-ME induces type I IFN (a
Figure 6 Analysis of eIF-2a and phospho eIF-2a protein levels. Western blot from osteosarcoma cells (A) and 4 representative osteosarcoma
tissues (C); Quantitation of densitometry signals from osteosarcoma cells (B) and osteosarcoma patient tissues (D). The cytoplasmic extracts
prepared from Vehicle control (Veh) and (10 μM) 2-ME-treated cells, and from normal (N) and osteosarcoma tumor (T) tissues were analyzed by
western blot hybridization using anti-eIF2a, anti-phophoeIF2a and anti-GADPH antibodies. The bands were analyzed by quantitative
densitometry. After western blot analysis, the signals from the corresponding bands were quantitated and the ratio of peIF-2a over eIF-2a was
determined after normalization to GAPDH.
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and b) mRNA levels in low and high tumorigenic osteo-
sarcoma cells. In MG63 cells, the mRNA levels increase
at 16 and 24 h. Whereas, in 2-ME-treated 143B cells,
IFNa increases at 16 h and IFNb mRNA increases at 8
and 24 h. While this biphasic induction needs to be stu-
died further, the late induction may be due to secondary
responses and to transcription factors that may be acti-
vated during early response. The induction of mRNA
appears to be due to the induction of gene promoter
activity. 2-ME-mediated induction of IFN promoter sug-
gests that 2-ME might recruit transcription factors (pro-
teins) that could directly bind to regulatory elements on
the IFN promoter. Previous studies show that (nuclear
factor kappa B) NFB, (interferon regulatory factor)
IRF-1 and P53 proteins directly bind to IFN gene
sequences and induce transcription. 2- ME-mediated
anti-tumor effects in osteosarcoma cells and in several
other systems involve the induction of P53 [6,19].
Further work is needed to determine whether P53 or
other protein transcription factors are involved in these
biological effects of 2-ME and contribute to 2-ME-
stimulated responses and IFN promoter activities.
IFN-mediated transcriptional activation and signaling
has been well studied by several investigators using var-
ious model systems [9]. IFN actions trigger a cascade of
events leading to ISRE and GAS dependent transcrip-
tional events [20,21]. While ISRE effect is mainly
induced through the type I IFNs, IFNa and IFNb [22],
the GAS effects are induced by type II IFN family mem-
ber, IFNg. [23]. Our results show that 2-ME treatment
increased transcription of ISRE- dependent transcription
in MG63, 143B, KHOS and HOS osteosarcoma cells.
Similarly, GAS-dependent transcription is increased in
MG63, 143 and KHOS osteosarcoma cells but not in
HOS cells. This differential response could be due in
part to the differences in cell origin and the genetic het-
erogeneity of osteosarcoma. GAS and ISRE activations
are due to specific activation of JAK/STAT family mem-
bers and formation of dimeric complexes of STAT
family members in cytoplasm and translocation into
nucleus [9,20,24]. However, detailed investigations are
required to identify the nature of hetero- and homo-
dimers that might be forming in 2-ME-treated cells and
contributing to the activation of ISRE and GAS
elements.
2-ME treatment does not affect IFN promoter activity
or gene expression and IFN-regulated pathways in nor-
mal HOB cells. We have previously demonstrated that
2-ME induces anti-growth activities in several osteosar-
coma cell lines but not in normal primary HOB cells
[5]. Current studies suggest that there is an association
between 2-ME-induced anti-proliferative effects and the
induction of IFN pathways in 2-ME-treated osteosar-
coma cells.
IFN was approved nearly three decades ago for clinical
applications. IFN-a2 remains a mainstay of treatment
for viral infections and certain forms of cancer including
osteosarcoma. Studies have shown that the protein pro-
ducts of IFN, the couple of hundred IFN stimulated
genes (ISGs), underlie the biological and clinical effects
of IFNs [9,11]. They provide fundamental cellular
defense mechanisms against viral infections and cancer.
Studies from other groups have shown that co-treat-
ment of IFN improves the anti-tumor effects of che-
motherapeutic agents such as doxorubicin and etoposide
[15]. The European American oncology study group
(EURAMOS) is investigating the effect of IFN as a fol-
low up therapy in patients who have undergone conven-
tional chemotherapy[10,12]. Furthermore, IFN has been
shown to increase the chemotherapy sensitivity of osteo-
sarcoma cell lines [25]. Although additional work is war-
ranted to delineate these molecular pathways in 2-ME
treated osteosarcoma cells, our findings point out that
IFN signaling could play important role in the control
of osteosarcoma.
IFN-regulated anti-tumor mechanisms are mediated
by eukaryotic initiation factor(eIF)-2, and through the
down-regulation of protein synthesis [26,27]. EIF-2-
mediated mechanism has been well documented in IFN-
treated cells and in several other cancer models [27].
EIF-2 forms a ternary complex with GTP and MET-
tRNA and delivers the initiation factor tRNA to the
ribosomal site of protein synthesis [26,28-30]. The eIF-2
is discharged and released as a complex with GDP. This
GDP should be replaced with GTP in order for eIF-2 to
form a new ternary complex and trigger a new set of
translation initiation. The phosphorylated form of eIF-2
is not able to trigger initiation resulting in the inhibition
of protein synthesis [26-28]. Our work from previously
published reports and from current studies indicate that
2-ME treatment results in the phosphorylation of eIF-
2a protein in vitro. The regulation is specific to anti-
growth activities of 2-ME since 2-ME does not appear
to regulate eIF-2a in HOB cells. Our analyses of tissue
specimens from patients show decreased levels of the
phosphorylated form of eIF-2a protein in osteosarcoma
tissues compared to normal (Table 1). The disease spe-
cific regulation was observed in 11 out of 15 specimens.
The eIF-2a phosphorylation is associated with osteosar-
coma independent of organ and histology subtype as
summarized in Table 1. This raises the possibility that a
cause for tumor progression could be the decreased eIF-
2a phosphorylation which eventually results in
decreased inhibition of protein synthesis and apoptosis
in tumor cells. Additional data involving a large number
of tissues would be necessary to conclude whether the
apparent difference in phosphorylation reflects the
apparent differences in growth regulation between
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normal and tumor tissues. These observations further
corroborate our findings that exposure to 2-ME leads to
increased phosphorylation of eIF-2a resulting in
increased apoptotic and anti-tumor effects due to the
inhibition of protein synthesis in osteosarcoma cells
[18]. These investigations point out that decreased IFN-
signaling could be potentially associated with the disease
state in osteosarcoma tissues. Recent studies show that
IFN inhibitory activity in osteosarcoma patients could
be an important factor that contributes to tumor pro-
gression. Inhibition of IFN pathways could lead to
increased susceptibility to disease and progression of
disease to metastatic stages [31]. These findings and our
current results emphasize that understanding of IFN sig-
naling could help diagnose and provide optimal therapy
in osteosarcoma patients.
Conclusions
In conclusion, we have shown that IFN signaling is asso-
ciated with osteosarcoma regulation and 2-ME-mediated
cell death in osteosarcoma cells. Hence, upregulation of
IFN pathway could be an effective strategy for control-
ling osteosarcoma.
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